BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 33321903)

  • 1. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
    Le TBU; Vu TC; Ho RZW; Prawira A; Wang L; Goh BC; Huynh H
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infigratinib Mediates Vascular Normalization, Impairs Metastasis, and Improves Chemotherapy in Hepatocellular Carcinoma.
    Huynh H; Lee LY; Goh KY; Ong R; Hao HX; Huang A; Wang Y; Graus Porta D; Chow P; Chung A
    Hepatology; 2019 Mar; 69(3):943-958. PubMed ID: 30575985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts.
    Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H
    Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of the ErbB family by EZH2 in hepatocellular carcinoma confers resistance to FGFR inhibitor.
    Prawira A; Le TBU; Ho RZW; Huynh H
    J Cancer Res Clin Oncol; 2021 Oct; 147(10):2955-2968. PubMed ID: 34156519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
    Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
    Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribociclib enhances infigratinib-induced cancer cell differentiation and delays resistance in FGFR-driven hepatocellular carcinoma.
    Prawira A; Le TBU; Vu TC; Huynh H
    Liver Int; 2021 Mar; 41(3):608-620. PubMed ID: 33179425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
    Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
    Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression.
    Xiong YQ; Sun HC; Zhu XD; Zhang W; Zhuang PY; Zhang JB; Xu HX; Kong LQ; Wu WZ; Qin LX; Tang ZY
    J Cancer Res Clin Oncol; 2011 Mar; 137(3):505-12. PubMed ID: 20490863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mTOR inhibition improves fibroblast growth factor receptor targeting in hepatocellular carcinoma.
    Scheller T; Hellerbrand C; Moser C; Schmidt K; Kroemer A; Brunner SM; Schlitt HJ; Geissler EK; Lang SA
    Br J Cancer; 2015 Mar; 112(5):841-50. PubMed ID: 25688743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
    Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
    Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
    Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of FGFR Inhibitors and Combination Therapies for Acquired Resistance in FGFR2-Fusion Cholangiocarcinoma.
    Krook MA; Lenyo A; Wilberding M; Barker H; Dantuono M; Bailey KM; Chen HZ; Reeser JW; Wing MR; Miya J; Samorodnitsky E; Smith AM; Dao T; Martin DM; Ciombor KK; Hays J; Freud AG; Roychowdhury S
    Mol Cancer Ther; 2020 Mar; 19(3):847-857. PubMed ID: 31911531
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
    Wang H; Zhang C; Chi H; Meng Z
    Int J Oncol; 2018 Jun; 52(6):2051-2060. PubMed ID: 29620259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of FGFR Reactivates IFNγ Signaling in Tumor Cells to Enhance the Combined Antitumor Activity of Lenvatinib with Anti-PD-1 Antibodies.
    Adachi Y; Kamiyama H; Ichikawa K; Fukushima S; Ozawa Y; Yamaguchi S; Goda S; Kimura T; Kodama K; Matsuki M; Miyano SW; Yokoi A; Kato Y; Funahashi Y
    Cancer Res; 2022 Jan; 82(2):292-306. PubMed ID: 34753772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
    Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
    Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
    Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A
    Oncology; 2018; 94(6):329-339. PubMed ID: 29719302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
    Bagi CM; Gebhard DF; Andresen CJ
    Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
    Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
    J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dovitinib demonstrates antitumor and antimetastatic activities in xenograft models of hepatocellular carcinoma.
    Huynh H; Chow PK; Tai WM; Choo SP; Chung AY; Ong HS; Soo KC; Ong R; Linnartz R; Shi MM
    J Hepatol; 2012 Mar; 56(3):595-601. PubMed ID: 22027573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.